Cardiovascular (CV) risk is typically determined on the basis of the 2 major components of the pressure waveform: the steady component, assessed by mean arterial pressure (MAP), and the pulsatile component, assessed by pulse pressure (PP). Principal component analysis 1 has shown the steady and the pulsatile components of brachial (b) blood pressure (BP) to be independent predictors of CV mortality. Furthermore, gender-and age-related differences in terms of the ability of MAP and PP to predict CV mortality have been identified. 1 Several studies of a large cross-sectional population (N = 69,989; age 40-69 years; mean follow-up, 9.5 years) showed the specific influence of MAP and PP on CV mortality as based on brachial artery BP measurements. 2 Over the past 20 years, the ability of central (c)PP to predict mortality and CV events, independently from bPP or MAP, has also been recognized. [3] [4] [5] [6] [7] [8] [9] While the correlation between cPP and organ damage in adults, 3-9 and adolescents 10 appeared stronger than that of bPP, the potential clinical impact of this finding in terms of improved medical practice remains unknown. 11 Recently, 24-hour ambulatory recordings showed that cardiac hypertrophy is more closely associated with aortic PP than bPP. 12 These data were obtained from cross-sectional studies that evaluated BP at one single timepoint. It is therefore useful, particularly in untreated individuals, to delineate the association between longitudinal changes in BP and mortality by studying its steady and pulsatile components separately. Given the age-and 
gender-modulated differences between bPP and cPP, 13, 14 we hypothesized that each likely exhibits unique traits.
The primary objective of our study was to investigate the associations between, on one hand, MAP, bPP, and cPP (the latter using validated algorithms) changes per year observed at 2 consecutive health checkups, and on the other hand, allcause mortality. The study was conducted in a vast population in France without BP-lowering drug therapy. The secondary objective was to determine whether these tentative associations were similar in men and in women, and in both younger and older participants. The aim of this longterm longitudinal study was to identify factors typically observed in clinical practice that were likely to distinguish the distinct potential of MAP from that of PP in terms of predictive value; we did not seek to define and/or compare the respective contributions of MAP and PP. Furthermore, this study did not set out to investigate the potential superiority of peripheral vs. cPP, nor to suggest that cPP should be measured in clinical practice with the validated mathematical formulas we used, although these are applicable in large epidemiological studies.
POPULATION AND METHODS

Population
The study population comprised 71,629 individuals (M: 47,984; F: 23,645; age 16-95 years), attending the Clinical and Preventive Investigation Center (Investigations Préventives et Cliniques [IPC] ), Paris, France. This center conducts approximately 25,000 checkups per year for people living in the Paris area. Each participant had 2 checkups (visit 1 [v1] and v2) between January 1992 and December 2011. None were being treated for hypertension. The mean interval between checkups was 5.8 ± 2.4 years. The methodology and scheduling of both visits were similar. Permission was granted to the IPC Center (authorization number 96020) by the French National Data-protection Agency (Commission nationale de l'informatique et des libertés [CNIL] ) to conduct analyses (including ethical aspects) on all data collected during the checkups. All participants provided informed consent at v1.
BP measurements
Using an appropriate cuff size, 15 brachial BP was measured 3 times after a 10-minute rest in the supine position. The mean of the last 2 measurements was documented in the database. Until mid-1998, manual mercury sphygmomanometers were used to measure systolic BP (SBP) and diastolic BP (DBP); they were subsequently replaced by validated digital electronic BP measurement devices such as that of A & D, model TM-2541 (A&D Company, Tokyo, Japan). O'Brien et al. 16 showed that these devices provide SBP measurements that are 2 mm Hg and DBP 1 mm Hg lower than those of a standard mercury sphygomanometer. Given that our study spanned this period of transition, our BP measurements were modified accordingly. We and others have previously verified the validity of such calculations, in both cross-sectional and longitudinal investigations. 17, 18 MBP (defined as DBP plus one third SBP minus DBP) and PP (defined as SBP minus DBP) were calculated concurrently. Height was measured with a wallmounted stadiometer and participants were weighed (wearing underwear) using calibrated scales. Standard biological parameters, including total plasma cholesterol and triglycerides, were measured under fasting conditions. Heart rate was determined using a 10-cycle electrocardiogram (Cardionics ZM286LP, Cardionics S.A., Brussels, Belgium). Tobacco consumption, physical activity, personal and family medical history, and current medications were documented using a standardized self-administered questionnaire. Physical activity was assessed by the yes/no question, "Do you regularly do some form of physical exercise equivalent to at least one hour walking per day?. " Tobacco consumption was classified according to 3 groups: never smokers, ex-smokers, and current smokers.
Carotid PP was calculated using a previously validated regression model based on 2 separate cohorts as previously published. 9, 19 Gender-specific models were obtained as follows:
• men: cPP (mm Hg) = 2. [current] . To validate this procedure, a random sample of 364 subjects considered as deceased in our database, were assessed in 2012. Mortality data were compared with those from city hall registries for every candidate. Discordance was only found in 2 cases (0.55%). On the basis of this validation, follow-up data of deceased individuals were considered accurate for the entire study population. Mortality data were available for this population until December 2011. Mean follow-up after v2 was 6.9 ± 3.3 years. During this period, 2,033 deaths were recorded.
Statistical analysis
All individuals treated for hypertension were excluded from the analysis. Of the 71,629 totally treatment-naïve individuals assessed at v1 and v2, the annual pressure change between visits v1 and v2 was calculated. For each individual, this implied calculating the ratio between the pressure change and the time interval between v1 and v2, expressed in mm Hg/year, in each case for bPP, cPP, and MAP. Each of these 3 variables was then divided into quartiles (Table 1) . Quartiles 1 and 4 of the bPP, cPP, and MAP changes, expressed in mm Hg/year, had either negative (quartile 1) or positive (quartile 4) values, respectively. Because the extreme limits of quartiles 1 and 4 were −1 (upper limit of quartile 1) and +1.7 (lower limit of quartile 4) mm Hg/ year bPP, these 2 distinct limits were used to define quartiles 2 and 3 as the 2 quartiles where no significant changes in mm Hg/year were observed. Thus, a reference (REF) group that included quartiles 2 and 3 was defined. These definitions are further explained in the Results section.
The association between the changes in bPP, cPP, and MAP (change/year, mm Hg/year) and the risk of mortality was then evaluated for all-cause mortality using Cox regression models including age, gender, body mass index, cholesterolemia, glycemia, gamma-Gt, physical activity, tobacco consumption, heart rate, and the corresponding hemodynamic variable (bPP, central PP, MAP) observed at v1. To evaluate the effect of gender on the association between hemodynamic factors and mortality, the analysis was performed in the overall population as well as in subgroups (men-women). The effect of interaction between: (i) gender and the change in each hemodynamic parameter (i.e., the change in bPP, or cPP, or MAP), as well as between (ii) age subgroups (younger [<55 years] and older individuals [≥55years]) and each hemodynamic parameter on all-cause mortality was also tested. On the basis of previous results, a cutoff value of age 55 years was used. 1, 2 A P value of <0.05 was considered statistically significant. Analyses were carried out using the SAS software package (version 8.02 for Windows) where mean values are presented with SD. Table 1 presents the main hemodynamic characteristics of the population (bPP change/year, cPP change/year, MAP change/year). The 1st quartile corresponds to a negative change/year, i.e., decrease in bPP, cPP, and MAP; the 2 nd and 3 rd quartiles correspond to the group with no change/year (i.e., the subgroup used as the reference group, REF, in the subsequent regression analysis); the 4 th quartile corresponds to the group with a positive change/year, i.e., increase in bPP, cPP, and MAP. There was a significant (P < 0.001) progressive increase from the first to the last quartile in all hemodynamic variables. Table 2 shows the baseline (v1) characteristics of the different variables according to bPP changes (upper panel) and cPP changes (lower panel). Compared to other groups, individuals with a positive change (increase) in bPP were older, had lower baseline bPP, lower baseline SBP, lower tobacco consumption, lower physical activity, higher body mass index, higher glycemia, were more likely to be diabetic, had higher cholesterolemia, higher DBP, and a higher rate of absolute all-cause mortality. No differences were observed with regard to heart rate. The 71,629 subjects of the v1 population were divided into quartiles. *P value represents comparison between changes. Abbreviations: BP, blood pressure; MAP, mean arterial pressure; PP, pulse pressure.
RESULTS
a Outlier values were excluded. Table 3 (3A to 3C correspond to bPP, cPP, and MAP, respectively) shows the relationship between changes (positive or negative, compared to the REF group) in terms of hemodynamic parameters and all-cause mortality in the overall population according to gender, using Cox regression models including age, gender, body mass index, cholesterolemia, glycemia, gamma-Gt, physical activity, tobacco consumption, heart rate, and the corresponding hemodynamic variables (bPP, cPP, MAP) observed at v1. The subgroup with yearly increases in bPP had a 200% increase in the risk of all-cause mortality in comparison with the reference group (Table 3A) ; this association was comparable in men and women (interaction between a positive annual change in bPP and gender was not significant). In contrast, in the overall population, and in both genders, there was no association between a negative annual change (decrease) in bPP and all-cause mortality. Results regarding cPP (Table 3B) were similar to those obtained for bPP, except for an additional inverse association between a negative annual change (decrease) in cPP and the risk of all-cause mortality, which notably was only observed in men. However, the interaction between a positive annual change in cPP and gender was not significant. In the overall population, the subgroup with a positive change (increase) in MAP had a 68% increase in all-cause mortality (Table 3C ). Although a negative change (decrease) in MAP did not affect all-cause mortality in the overall population, we did observe an association between this parameter and all-cause mortality in women. However, no interaction between men and women was observed regarding the impact of positive or negative changes in MAP on all-cause mortality.
In the last part of the explorative analysis (Figure 1) , we studied the hazard ratio (HR) for mortality risk associated with positive (increase) or negative (decrease) changes in hemodynamic factors in both men and women according to age, using 55 years as the cutoff value. An interaction between age-group and positive changes (but not with negative bPP changes) in brachial (Figure 1a , upper panel) and cPP (Figure 1b, lower panel) was noted in both genders. In men, the risk of all-cause mortality associated with The 71,629 subjects of the v1 population were divided into quartiles. Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; HR, hazard ratio; PP, pulse pressure; SBP, systolic blood pressure.
a positive change of 1 mm Hg/year in bPP was 1.61 (hazard ratio [95% confidence interval], 1.32-1.96; P < 0.001) and 0.94 (0.61-1.55; P = 0.8) in the <55-year and ≥55-year agegroups, respectively. The impact of bPP changes on mortality differed slightly between the 2 groups (P < 0.005 for interaction). In women, the risk of mortality associated with a positive change of 4 mm Hg/year in bPP observed in the 2 age-groups was 1.23 (1.06-1.42; not significant), and 1.62 ([1.26-2.07]; P < 0.001), in the <55-year and ≥55-year agegroups, respectively. A slightly significant age-interaction was observed in women (P < 0.06). Similar results were found for a positive change in cPP (Figure 1b, lower panel) . Regardless of gender, no interactions were found between changes (positive or negative) in MAP and age, and their association with all-cause mortality.
DISCUSSION
This study was conducted in a vast population of over 72,000 individuals in France, none of whom were on antihypertensive drug therapy. Over an average follow-up period of 6 years, we studied the links between longitudinal annual changes in both the steady (MAP) and pulsatile (bPP and cPP) components of the pressure waveform, and the incidence of all-cause mortality.
We identified major differences in the association of each pressure waveform component with the incidence of all-cause mortality. These differences were all the more pronounced when the roles of age and gender were taken into consideration.
Methodological considerations: strengths and limitations
The results of this study differ from those of conventional clinical trials. They are derived from a vast longitudinal study summarizing different aspects of the evolution of BP in a total of 71,629 individuals. Typically, for this purpose, conventional regression models are generally used to calculate the slope in a number of BP measurements in order to obtain clear-cut longitudinal changes, in many cases over a period of no more than 1 year. In the present study, although only 2 measurements were done at v1 and v2, they were in reality assessed in the context of long-term evolution over approximately 4.8 years and also in a notably large number of individuals. In addition, it is noteworthy that throughout the entire period of investigation, no antihypertensive drugs were used. This methodology, based specifically on the study of MAP and PP as observed in well-known physiological conditions appears to be well adapted to clinical practice and above all, to medical decision-making. Furthermore, our analysis focused exclusively on all-cause mortality. Causes of CV death were not investigated because autopsy data were not systematically available. For this reason, the associations we observed between hemodynamic parameters and overall mortality cannot imply causality. Furthermore, it is important to note that the cPP-related data must be interpreted with caution since they derive from post-hoc estimation based on a validated mathematical formula 9, 19 and not from individual dedicated cBP-assessment. However, given the study sample-size, the present methodology appears legitimate and has provided particularly insightful data.
Prognostic significance of different BP components
The first main finding, after adjusting for confounding factors, was that the subgroup with a yearly increase in either bPP or cPP had a 200% higher relative risk of allcause mortality in comparison with the reference group, whereas the subgroup with a yearly increase in MAP had only a 68% higher relative risk of all-cause mortality. This finding suggests that even in middle-aged individuals (mean age of 4 th quartile, 49 years; Table 1 ), a small yearly longitudinal increase in PP has a significantly deleterious impact on the incidence of mortality. Moreover, and although the relative yearly changes in PP and MAP (i.e., 1/54 vs. 1/95, respectively) are not of the same magnitude, these findings were limited to provide a clinical interpretation of the relative impact of both the steady (MAP) and the pulsatile (PP) components of BP on all-cause mortality rather than a direct comparison.
Secondly, our data show that a yearly decrease in peripheral and cPP (the latter particularly in men) tends to be associated with a reduced incidence of all-cause mortality. In contrast, although MAP reductions per year were not associated with a reduced incidence in mortality, they were significantly correlated with increased all-cause mortality in men. This finding, although to be interpreted with caution in view of the aforementioned limitations and the potential regression to the mean phenomenon, could be explained by the low (i.e., normal) BP levels at baseline, or the potential presence of other non-CV and/or CV comorbidities (such as heart failure 20 or cachexia) that lower MAP, leading to a J-shaped phenomenon. Most importantly, the strikingly different patterns of association between yearly PP progression and all-cause mortality compared to the corresponding association with yearly MAP progression, clearly showed that the 2 components of the pressure waveform convey different and mutually independent predictive information. In terms of arterial mechanics, this should be considered as a phenomenon that is largely related to different pathophysiological mechanisms (low cardiac output and total peripheral resistance vs. arterial stiffness) underlying the genesis and progression of each component. Third, it should also be noted that the subgroup of individuals (4 th quartile, Table 2 ) who experienced an increase in PP (peripheral and central) between v1 and v2, had low baseline PP (45.6 mm Hg) but higher age (49.7 years), compared to the other subgroups, particularly the subgroup who experienced a decrease in PP (baseline PP, 56.3 mm Hg; age, 44.7 years). As far as PP can be considered as a reliable surrogate for arterial stiffening/aging, this finding suggests, independently of age and the age-related onset of arterial stiffening, that the relative risk of all-cause mortality is constantly increased in the presence of arterial stiffening (PP increase) and tends to decrease in the presence of arterial de-stiffening (PP decrease).
Fourth and particularly importantly, the present findings highlight the impact of age and gender on the association between the pulsatile components of BP and all-cause mortality, and which was not observed with regard to the association between the steady components of BP and all-cause mortality. In men, the yearly PP increase was associated with a greater incident all-cause mortality in younger men (<55 years) than in older men (≥55 years) whereas results were quite the contrary in women. Differences in terms of CV disease and risk factors, especially in older individuals, have been previously described. 21 In women >55 years, it is widely acknowledged that, independently of the standard aging process, the loss of estrogenic action in the carotid and brachial arterial wall can exert a specific deleterious effect, thus increasing arterial stiffness and reducing vascular elasticity. [22] [23] [24] In contrast, it should be noted that in men, the well-established age-related increase in aortic stiffness 25, 26 does not result in the same epidemiological consequences as in women. However, in postmenopausal women, estrogen treatment is not constantly associated with improvements in arterial stiffness. Other working hypotheses must therefore be considered. Recent studies in women >60 years have shown that aortic stiffness or PP may be associated with the presence of free tissue factor pathway inhibitor. Free tissue factor pathway inhibitor levels increase as vascular function deteriorates and PP increases. 27 Such findings are supported by the increased tissue factor pathway inhibitor synthesis by vascular smooth muscle in response to cyclic stress, but not to steady stress. Thus, vascular smooth muscle requires pulsatility to interfere with the coagulation process and may potentially favor vascular alterations.
Finally, close investigation of cPP and bPP showed that both factors exhibit similar overall associations with allcause mortality. However, given the aforementioned limitations, the yearly decrease in cPP was significantly correlated with reduced incidence of all-cause mortality, whereas bPP showed a similar though nonsignificant trend. Moreover, slightly stronger associations in men, but lower in women, were found between yearly increases in cPP and all-cause mortality, compared with the corresponding relative risk provided by bPP. The hypothetical clinical superiority of cPP over bPP, which may be true in specific populations, is a subject that warrants further study in specifically designed clinical trials.
In conclusion, the longitudinal study of changes occurring in the steady and pulsatile components of BP may have an important impact on normotensive individuals who are not receiving antihypertensive drug therapy. Findings may also identify specific factors to improve assessment of hypertension and its prognosis. MAP and PP both have the potential to impact on all-cause mortality with major differences concerning their specific ability to integrate the effects of age and gender, which are better depicted with PP (especially cPP) than MAP. Whether the 2 components of BP should be considered as distinct targets to address the known differences in the effects of antihypertensive agents on men and women 28, 29 should be addressed in further research. This aspect may have important consequences in routine clinical practice, particularly in older individuals where elevated PP is a particularly important consideration.
